메뉴 건너뛰기




Volumn 8, Issue 1, 2013, Pages 23-28

The PARAMOUNT trial: A phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

Author keywords

Advanced NSCLC; Cisplatin; Continuation maintenance; Erlotinib; Pemetrexed; Switch maintenance

Indexed keywords

CISPLATIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; PEMETREXED; PLACEBO; PLATINUM;

EID: 84874902168     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/15748871112079990040     Document Type: Article
Times cited : (6)

References (19)
  • 2
    • 33750603100 scopus 로고    scopus 로고
    • Changing epidemiology of small cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic and end results database
    • Govindan R, Page N, et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol 2006; 24: 4539-4544.
    • (2006) J Clin Oncol , vol.24 , pp. 4539-4544
    • Govindan, R.1    Page, N.2
  • 3
    • 0030912190 scopus 로고    scopus 로고
    • Revisions in the international system for staging lung cancer
    • Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
    • (1997) Chest , vol.111 , pp. 1710-1717
    • Mountain, C.1
  • 4
    • 34848849863 scopus 로고    scopus 로고
    • Treatment of nonsmall cell lung cancer: Stage IV: ACCP evidence-based clinical practice guidelines
    • (2nd Edition)
    • Socinski MA, Crowell R, Hensing TE, et al. Treatment of nonsmall cell lung cancer: stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest; 132 (suppl. 3): 277S-289S.
    • Chest , vol.132 , Issue.SUPPL. 3
    • Socinski, M.A.1    Crowell, R.2    Hensing, T.E.3
  • 5
    • 66549109768 scopus 로고    scopus 로고
    • Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
    • D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (suppl. 4): iv68-iv70.
    • (2009) Ann Oncol , vol.20 , Issue.SUPPL. 4
    • D'Addario, G.1    Felip, E.2
  • 6
    • 74949133978 scopus 로고    scopus 로고
    • American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
    • (2009) J Clin Oncol , vol.27 , pp. 6251-6266
    • Azzoli, C.G.1    Baker Jr., S.2    Temin, S.3
  • 7
    • 84860537353 scopus 로고    scopus 로고
    • Maintenance treatment of advanced non-small-cell lung cancer: Results of an international expert panel meeting of the Italian association of thoracic oncology
    • Gridelli C, De Marinis F, Di Maio M, et al. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 2012; 76: 269-279.
    • (2012) Lung Cancer , vol.76 , pp. 269-279
    • Gridelli, C.1    De Marinis, F.2    Di Maio, M.3
  • 8
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, doubleblind, phase 3 study
    • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase 3 study. Lancet 2009; 374: 1432-1440.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 9
    • 64049115311 scopus 로고    scopus 로고
    • The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies
    • Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
    • (2009) Oncologist , vol.14 , pp. 253-263
    • Scagliotti, G.1    Hanna, N.2    Fossella, F.3
  • 10
    • 84862781680 scopus 로고    scopus 로고
    • Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MCJMEN): Results from a randomised, double-blind, phase 3 study
    • Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MCJMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012; 13: 292-299.
    • (2012) Lancet Oncol , vol.13 , pp. 292-299
    • Belani, C.P.1    Brodowicz, T.2    Ciuleanu, T.E.3
  • 11
    • 77953541527 scopus 로고    scopus 로고
    • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
    • Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
    • (2010) Lancet Oncol , vol.11 , pp. 521-529
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 12
    • 25844468887 scopus 로고    scopus 로고
    • Accessed: April 25, European Medicine Agency, Summary of opinion (post authorisation): Tarceva. Available at
    • European Medicine Agency. Committee for medicinal products for human use (CHMP). Summary of opinion (post authorisation): Tarceva. Available at http://www.ema.europa.eu/pdfs/human/opinion/TarcevaII_8608010en.pdf Accessed: April 25, 2010.
    • (2010) Committee for medicinal products for human use (CHMP)
  • 13
    • 84859787320 scopus 로고    scopus 로고
    • Accessed: April 25, Food and Drug Administration, Available at
    • Food and Drug Administration. Highlights of prescribing information: Tarceva. Available at http://www.accessdata.fda.gov/drugsatfda_ docs/label/2010/021743s14s16lbl.pdf Accessed: April 25, 2010.
    • (2010) Highlights of prescribing information: Tarceva
  • 14
    • 84857507055 scopus 로고    scopus 로고
    • Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
    • Paz-Ares L, De Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
    • (2012) Lancet Oncol , vol.13 , pp. 247-255
    • Paz-Ares, L.1    De Marinis, F.2    Dediu, M.3
  • 15
    • 84867566940 scopus 로고    scopus 로고
    • PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
    • abstr LBA7507
    • Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: suppl abstr LBA7507.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Paz-Ares, L.1    De Marinis, F.2    Dediu, M.3
  • 16
    • 84862797797 scopus 로고    scopus 로고
    • Safety, resource use, and quality of life results from PARAMOUNT: A phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately following induction treatment with pemetrexed-cisplatin for advanced nonsquamous nonsmall cell lung cancer
    • (14 World Conference on Lung Cancer-Amsterdam, July 3-7, 2011)
    • Gridelli C, De Marinis F, Pujol JL, et al. Safety, resource use, and quality of life results from PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately following induction treatment with pemetrexed-cisplatin for advanced nonsquamous nonsmall cell lung cancer. J Thorac Oncol 2011; 6 (suppl 6): S323 (14 World Conference on Lung Cancer-Amsterdam, July 3-7, 2011).
    • (2011) J Thorac Oncol , vol.6 , Issue.SUPPL. 6
    • Gridelli, C.1    De Marinis, F.2    Pujol, J.L.3
  • 17
    • 80053639884 scopus 로고    scopus 로고
    • 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011; 29: 3825-31.
    • (2011) J Clin Oncol , vol.29 , pp. 3825-3831
    • Azzoli, C.G.1    Temin, S.2    Aliff, T.3
  • 18
    • 84857502282 scopus 로고    scopus 로고
    • Maintenance chemotherapy in advanced non-small cell lung cancer
    • Jassem J. Maintenance chemotherapy in advanced non-small cell lung cancer. Lancet Oncol 2012; 13: 217-218.
    • (2012) Lancet Oncol , vol.13 , pp. 217-218
    • Jassem, J.1
  • 19
    • 77955097091 scopus 로고    scopus 로고
    • Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer
    • Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010; 5: 1263-72.
    • (2010) J Thorac Oncol , vol.5 , pp. 1263-1272
    • Klein, R.1    Wielage, R.2    Muehlenbein, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.